Advertisement

Topics

A CASCADE Of Trouble For Seattle Genetics' AML Drug SGN-CD33A

12:35 EDT 19 Jun 2017 | SCRIP

Seattle Genetics will discontinue all trials of vadastuximab talrine, including the Phase III CASCADE trial in frontline older acute myeloid...

      

Related Stories

 

Original Article: A CASCADE Of Trouble For Seattle Genetics' AML Drug SGN-CD33A

NEXT ARTICLE

More From BioPortfolio on "A CASCADE Of Trouble For Seattle Genetics' AML Drug SGN-CD33A"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...